About Forus
Leadership
Values
Latest News
WELCOME, Erin Webb
FORUS Therapeutics is thrilled to welcome Erin Webb as Therapeutic Area Manager, Hematology/Oncology, SW ON. Erin began her career as a physician assistant in the US, caring for patients with both benign and malignant hematologic conditions as well as managing...
US-authorized BESREMi® Now Available
FORUS Therapeutics is pleased to announce that US-authorized BESREMi® (ropeginterferon alfa-2b-njft), is now available in Canada, via Exceptional Importation. Please note, BESREMi®’s active ingredient, ropeginterferon alfa-2b-njft, has not been reviewed under Health...
FORUS and PharmaEssentia Have Entered Into an Exclusive Licensing Agreement for The Registration and Distribution of BESREMi® for The Treatment of polycythemia vera (PV), in Canada
FORUS Therapeutics Inc. and PharmaEssentia Corporation have entered into an exclusive licensing agreement for the registration and distribution of BESREMi® (ropeginterferon alfa-2b) for the treatment of polycythemia vera (PV), in Canada. Under the terms of the...
Contact Us
Mailing Address:
FORUS Therapeutics Inc.
200 North Service Road West, Suite 129
Oakville, Ontario, L6M 2Y1
Phone: 1-877-359-9595
Fax: 1-877-359-9590
Patient Support:
Phone: 1-833-4YOUPSP (1-833-496-8777)
Fax: 1-833-4YOUFAX (1-833-496-8329)
Product Support:
Phone: 1-866-542-7500
Fax: 1-866-542-1100
Do not use this form to report adverse events. Adverse events can be reported at 1-866-542-7500.